News and Trends 21 Feb 2023 Biocytogen launches nanobody therapeutics project for 100 targets Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has launched the “Nano 100 Project,” which aims to develop fully human nanobody drugs for more than 100 targets. The project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale. Compared […] February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 FDA approves alpha-mannosidosis drug Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), says the U.S. Food and Drug Administration (FDA) has approved Lamzede (velmanase alfa-tycv) for the treatment of non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and pediatric patients. AM is an ultra-rare, progressive lysosomal storage disorder […] February 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by B2B - Breast2Bone 21 Feb 2023 From breast to bone: Refining metastasis drug discovery with a novel organ-on-a-chip device Understanding invasive cancer progression and metastasis formation are among the core open questions in cancer research. However, the limitations of current models lead to high failure rates in drug development. An EU-funded consortium has designed an organ-on-a-chip approach that could deliver new insights. In metastasis, circulating tumor cells spontaneously shed from the primary site to […] February 21, 2023 - 6 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
Interview 17 Feb 2023 The benefits – and challenges – of in-house CAR T-cell therapy The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better […] February 17, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Positive results for INOVIO recurrent respiratory papillomatosis trial INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Immuno Cure starts HIV drug trial Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park, which specializes in PD-1-enhanced DNA vaccines and immunotherapies, has started its phase I clinical trial of ICVAX, a therapeutic vaccine against HIV/AIDS. The trial is taking place at the National Clinical Research Center for Infectious Diseases at The Third People’s […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Avilar Therapeutics financing up to $75M to boost extracellular protein degraders pipeline Avilar Therapeutics has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders. The new financing takes the company’s total to $75 million. The seed round had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation by new investors Sanofi Ventures, […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Report: China leads the way with phase 1 studies Novotech, an Asia Pacific biotech CRO, has published a new global report on phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for phase 1 clinical trials in the last 10 years, reaching a share of 58% in […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics Our Beyond Biotech podcast 34 guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, recently started […] February 17, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Newron reports ‘striking’ schizophrenia study results Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […] February 16, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Maxion Therapeutics raises $16M to target GPCRs Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […] February 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 16 Feb 2023 Five things you need to know about using CRISPR/Cas9 commercially By Michael Arciero, vice president of intellectual property and corporate development, ERS Genomics CRISPR/Cas9 gene editing technology is a patented invention, so any commercial use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape for CRISPR/Cas9 is clearer than you may think. Here are the 5 key facts […] February 16, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email